期刊文献+

如何通过规范化的抗病毒治疗达到更高的治愈率 被引量:2

Achieve a higher cure rate via standardized antiviral therapy for chronic hepatitis C
原文传递
导出
摘要 在近10年的临床试验和实践中,确立了持续病毒学应答(sustainedviralresponse,SVR)为慢性丙型肝炎抗病毒治疗的目标。由于利巴韦林和聚乙二醇干扰素(Pe驴IFN)的应用可显著提高抗病毒疗效,从而确立了利巴韦林和Peg-IFN在慢性丙型肝炎抗病毒治疗中的地位。诸多因素可以影响慢性丙型肝炎的抗病毒治疗效果,而抗病毒治疗中病毒的变化与SVR的获得有显著的预测性和相关性,为了使每一位患者有最大的几率获得SVR,既要遵循慢性丙型肝炎抗病毒治疗的标准化和规范化,又要正确理解和应用“应答指导治疗(responseguidetherapy,RGT)”的原则。
作者 谢尧 李明慧
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2013年第6期408-409,共2页 Chinese Journal of Hepatology
关键词 肝炎 丙型 慢性 干扰素类 治疗 Hepatitis C, chronic Intcrfcrons Therapy
  • 相关文献

参考文献12

  • 1StraderDB, WrightT, ThomasDL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology, 2004, 39:1147-1171.
  • 2European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol, 2011, 55: 245-264.
  • 3Gheorghe L, BaculeaS. Cost-effectiveness of peginterferon alpha- 2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C. Hepatogastroenterology, 2010, 57: 939-944.
  • 4Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha- 2a is associated with higher sustained virologicalresponse than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology, 2010, 51: 1176-1184.
  • 5Marcellin P, Heathcote E J, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J Hepatol, 2007, 47: 580-587.
  • 6Diago M, Shiffman ML, Bronowicki JP, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology, 2010, 51: 1897-1903.
  • 7Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.Hepatology, 2008, 47: 35-42.
  • 8Shiffman ML,Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med, 2007, 357: 124-134.
  • 9Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol, 2005, 43: 425-433.
  • 10Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg- interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology, 2011, 54: 789-800.

同被引文献24

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部